Branded and Biosimilar Ophthalmology

A Contract Award Notice
by THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) (NSS)

Source
Find a Tender
Type
Framework (Supply)
Duration
1 year (est.)
Value
£21M
Sector
HEALTH
Published
24 Nov 2025
Delivery
To 24 Nov 2026 (est.)
Deadline
n/a

Related Terms

Location

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014

Geochart for 2 buyers and 9 suppliers

2 buyers

8 suppliers

Description

Supply of Branded and Biosimilar Ophthalmology to NHS Scotland.

Lot Division

1 Aflibercept (Eylea®)

Supply of Aflibercept (Eylea®) vials and Pre-filled Syringes to NHS Scotland. The Authority has awarded this Framework as a single supplier framework to a single Framework Participant.

Award Criteria
Logistics 5.0
PRICE 95.0
2 Aflibercept Biosimilar

Supply of Aflibercept Biosimilar vials and Pre-filled Syringes to NHS Scotland. The Authority has awarded this Framework as an unranked multi- supplier framework to five (5) Framework Participants.

Award Criteria
Logistcics 5.0
PRICE 95.0
3 Ranibizumab vials and Pre-filled Syringes

Supply of Ranibizumab Branded and Biosimilar vials and Pre-filled Syringes to NHS Scotland. The Authority has awarded this Framework as an unranked multi- supplier framework to two (2) Framework Participants.

Award Criteria
Logistics 5.0
PRICE 95.0
4 Faricimab (Vabysmo®)

Supply of Faricimab vials and Pre-filled Syringes to NHS Scotland. The Authority has not awarded this Framework to any suppliers.

Award Criteria
Logistics 5.0
PRICE 95.0

Award Detail

1 Unnamed (None)
  • Faricimab (Vabysmo®)
  • CONTRACT NOT AWARDED – NO SUCCESSFUL BIDDERS.
2 Bayer (Reading)
  • Aflibercept (Eylea®)
  • Num offers: 1
  • Value: £9,272,932
3 Mercury Pharmaceuticals (London)
  • Aflibercept Biosimilar
  • Num offers: 5
  • Value: £8,685,992 [share]
  • Awarded to group of suppliers.
  • Contractor is an SME.
4 Teva (Castleford)
  • Aflibercept Biosimilar
  • Num offers: 5
  • Value: £8,685,992 [share]
  • Awarded to group of suppliers.
5 Celltrion Healthcare (Slough)
  • Aflibercept Biosimilar
  • Num offers: 5
  • Value: £8,685,992 [share]
  • Awarded to group of suppliers.
  • Contractor is an SME.
6 MD Biologics (London)
  • Aflibercept Biosimilar
  • Num offers: 5
  • Value: £8,685,992 [share]
  • Awarded to group of suppliers.
  • Contractor is an SME.
7 Sandoz (Surrey)
  • Aflibercept Biosimilar
  • Num offers: 5
  • Value: £8,685,992 [share]
  • Awarded to group of suppliers.
8 Biogen Idec (Maidenhead)
  • Ranibizumab vials and Pre-filled Syringes
  • Num offers: 3
  • Value: £2,712,160 [share]
  • Awarded to group of suppliers.
9 Teva (Castleford)
  • Ranibizumab vials and Pre-filled Syringes
  • Num offers: 3
  • Value: £2,712,160 [share]
  • Awarded to group of suppliers.

CPV Codes

  • 33600000 - Pharmaceutical products

Indicators

  • Award on basis of price.

Other Information

The estimated value(s) referred to in Section II.1.5 cover(s) the twelve (12) month contract duration and the thirty six (36) month extension period of the framework agreement. (SC Ref:812873)

Reference

  • FTS 076640-2025

Domains